Chicago, IL. Dec 13, 2021. Infusion 51a and BioWise Capital brought their expertise together in partnership at the 75th PostGraduate Assembly in Anesthesiology (PGA), celebrated this weekend in New York City, to offer physicians the opportunity to co-invest as LPs into disruptive life sciences and biotechnology.
The PGA is sponsored by the New York State Society of Anesthesiologists, Inc and every year attracts upwards of 4,000 attendees from around the world, constituting a global platform for networking to discuss the latest science and technologies.
Together, Infusion 51a and BioWise help health specialists to access a diversified portfolio of over 20 innovative companies and can get significant discounts on share value because the companies are private and the size of our offer, from 20-70% below current valuations.
During the 3-day-long conference, Infusion 51a’s General Partner and CFO, Scott VanderMeer, and Amir Baluch, MD, Fund Manager of BioWise Capital, shared investment knowledge with over 500 physicians interested in adding biotech and private equity to their portfolio.
VanderMeer expressed his excitement about the future projects to begin: “We talked to hundreds of doctors over the weekend, and they were very receptive to us. It’s been a very productive couple of days, and we are excited to see how these conversations turn into results next year. There are a lot of great things to come from this Infusion 51a-BioWise alliance.”
Baluch also commented on the experience: “I’ve been doing this for some years now [investing in the Biotech sector], and it gives me great satisfaction to teach what I’ve learned to my physician colleagues and walk them through how they can benefit from this fast-growing industry. The best is yet to come in 2022”.
About Infusion 51a
Infusion 51a is an impact investment fund focused on Healthcare and Biotech while leveraging the booming industry of Precision Medicine. Precision medicine is a turning point within the Healthcare sector, with digital technologies and artificial intelligence leading to unprecedented opportunities for drugs discovery and development. The fund has several oncological assets under management derived from its diversified portfolio of clinical-stage companies.
For further information, please visit http://infusion51a.com or message scott@infusion51a.com.
About BioWise Capital
Biowise Capital is an opportunistic private equity fund investing in life science and biotech companies that are both disruptive and innovative. The firm has a portfolio of 20 companies and co-manages nearly 600MM of holdings.
For further information please visit https://biowisecapital2.com/contact-us/ or message abaluchmd@yahoo.com.
